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IS THE GAP BETWEEN MICRO – AND MACRO-
ECONOMIC ASSESSMENTS IN HEALTH CARE WELL 




Published as: Kotsopoulos N and Connolly MP. Is the gap between micro- and 
macroeconomic assessments in health care well understood? The case of vaccination 
and potential remedies. Journal of Market Access & Health Policy (2014), 2: 23897 – 
h p://dx. Doi. Org/10.3402/jmahp. V2.23897 
Summary
Vaccination is an established intervention that reduces the burden and 
prevents the spread of infectious diseases. Investing in vaccination is known 
to off er a wide range of economic and intangible benefi ts that can potentiate 
gains for the individual and for society. The discipline of economics provides 
us with microeconomic and macroeconomic methods for evaluating the 
economic gains attributed to health status changes. However, the observed gap 
between micro and macro estimates attributed to health presents challenges to 
our understanding of health-related productivity changes and consequently 
economic benefi ts. The gap suggests that the manner in which health-
related productive output is quantifi ed in microeconomic models might not 
adequately refl ect the broader economic benefi t. We propose that there is a 
transitional domain that links the micro- and macro-economic improvement 
attributed to health status changes. Currently available economic evaluation 
methods typically omit these consequences however; they may be adjusted 
to integrate these transitional consequences. In practical terms this may give 
rise to multipliers to apply towards indirect costs to account for the broader 
macroeconomic benefi ts linked to changes in health status. In addition it 
is possible to consider that diff erent medical conditions and health care 
interventions may pose diff erent multiplying eff ects suggesting the manner 
in which resources are allocated within health services gives rise to variation 
in the amount of micro-macro gap. An interesting way to move forward in 
integrating the micro and macro-level assessment might be integrating 
computable general equilibrium (CGE) models as part of the evaluation 
framework as recently performed for pandemic fl u and malaria vaccination. 
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The economics of health and disease prevention
The economic benefi t of a healthy work force on improved productivity 
has been supported by a range of micro-level evaluations observed in both 
developed and developing countries1, 2, 3, 4. Instinctively if people are healthy 
their capacity to deliver labor to the market is enhanced and absenteeism 
avoided. Similar conclusions can be drawn for preventative interventions 
that avoid illness all together. These microeconomic evaluations have been 
presented in both the developed and the developing world1, 2, 3, 4. When 
looking at macroeconomic assessment the evidence has shown that country 
specifi c economic growth rates contribute to better health and increased life 
expectancy. This relationship occurs through a number of channels including 
improved access to health care, more nutritious food, improved sanitation 
and living conditions and the relationship between good health and income 
which is likely bi-directional5, 6. 
Building on the above reasoning, we observe that vaccination is one of 
the most powerful tools to prevent the spread of infectious diseases in a 
community. Therefore investing in vaccination can off er a range of economic 
benefi ts of which some are immediate, others may take generations to 
materialize. However, the benefi t of reducing health care expenditure 
attributed to infectious diseases is perhaps the most frequently described 
one where vaccines have repeatedly shown to generate signifi cant health 
care savings7. These health cost savings are the focus of most microeconomic 
evaluations. Meanwhile, focusing solely on health costs one may overlook the 
broader benefi ts gained and that may not be well captured in microeconomic 
evaluation frameworks. The benefi t of vaccines should be amplifi ed because 
much more is achieved through the improved health outcomes that, in turn, 
result in changes in behaviour and human capital accumulation hence, giving 
rise to benefi t to be observed at the higher, macro level. The best examples 
for that are the pre-pandemic fl u vaccination programs that impact on short 
term and micro- and macroeconomic parameters8. There have been attempts 
to establish the long term impact of pandemic on the economic growth of 
a country, through the decline in high -school graduation, decreased wages, 
and the increased likelihood of poverty. These assessments used the 1918 
pandemic as a basis9. They latter aff ect the individual but also accrue for 
a signifi cant time post a pandemic aff ecting the economy at a pronounced 
level10. Further evidence of the broader vaccine benefi ts related to improved 
health condition are vaccines likely to infl uence education attainment which 
can lead to greater lifetime earnings11. Thus, for vaccines there is evidence 
suggesting that analysis should go beyond the simple evaluation of micro-
economic fi ndings in order to highlight the total benefi t. 
Chapter 8
115
Economic assessments off er several micro- and macro-evaluation tools that 
can be used to investigate the benefi ts. However, most published economic 
evaluations of vaccines to date have been microeconomic focusing solely on 
cost-eff ectiveness. Fewer economic assessments project the macroeconomic 
benefi ts of vaccinations. Both levels of economic assessment are useful for 
decision making and for resource allocation decisions however, they may 
lead to diff erent results with diff erent consequences and we will expand more 
on these later in this paper. At the micro-level, it is expected that economic 
assessments will inform the price setting of vaccines. At macro-level they may 
inform the prioritization of competing investment initiatives that are deemed 
as advantageous for the economy. 
Surprisingly, there is a known discrepancy in the output reported between 
micro- and macro-economic evaluations when the analysis is performed 
separately. This was recently described in a published review assessing the 
impact of malaria. Malaney et al.,12 reported that the macroeconomic estimates 
for the impact of malaria on the GDP ranged from 0.25% to 1.3% whereas the 
projection of the microeconomic studies to the overall economy suggested 
a lower economic impact (GDP impact ranged from 0.14%-0.62%). The 
diff erence between the two evaluation methods does not seem large, but a 1% 
diff erence in GDP attributed to one disease that can be prevented is meaningful. 
An explanation for the diff erence between micro and macro estimates could 
be attributed to less well defi ned broader benefi ts that can lead to economic 
consequences at the level of microeconomic assessment that are often omitted. 
This paper advocates for macroeconomic modelling alongside 
microeconomic approaches. The benefi t of analysing both perspectives is 
that a combined assessment may more pragmatically quantify the broader 
economic consequences of investing in vaccines. The combined micro and 
macro data can then allow decision-makers to allocate resources to achieve 
health and economic priorities. The scope of macroeconomic evaluation is 
diff erent from “value for money” microeconomic assessments that are widely 
used in therapeutic drugs. In vaccines the focus is to capture in addition 
the rate of return of public health investment13, 14. Thus, microeconomic 
methods alone may not be suffi  cient from a policy analysis perspective. 
We hereby describe and critically appraise current microeconomic and 
macroeconomic assessment methods in terms of the ability to encapsulate 
the broader benefi t of prevention and its relevance for decision makers. 
Moreover, we defi ne the “transitional” economic consequences that may 
result from preventing communicable-diseases between the micro and macro 
level. In addition, this paper analyses the diff erences observed between 
micro and macro assessments. This identifi ed void should motivate further 
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methodological research. It is likely that an intermediate or “transitional” or 
“meso-economic” domain that could be thought of as a gateway by which the 
micro and macro economy of health are connected. This domain may provide 
with an explanation of the diff erences observed between micro and macro-
economic outcome results. 
Quantitative micro- and macro-economic analytical methods
Microeconomic analysis
Microeconomic analysis captures the cost of a communicable disease 
and the value of prevention for the individual at a community level. The 
starting point for this analysis is the measurement of the disease burden. 
These methods quantify the natural history of the disease (frequency in 
function of demography), disease management cost, and quality of life 
impact. The disease burden estimates are part of a cost-eff ectiveness or cost-
utility analysis that compares alternative health care interventions. The 
analyses address estimates of incremental cost and outcome of the diff erent 
interventions considered such as vaccination compared to no vaccination. 
The costing is typically based on a prospective algorithmic simulation of 
short-term natural history and treatment pathways of a disease15. Outcomes 
may be measured in terms of cases prevented, survival gained (life years 
gained), quality-adjusted survival gained (QALYs gained) or disability adjusted 
life years gained (DALYs gained) from the intervention. Although, quality of 
life self-reported assessments allow the inclusion of preferences, this short-
term and simplifi ed microeconomic framework would not quantify broader 
consequences such as changes in economic behaviors, school attendance and 
school attainment. It is only through longer term macroeconomic observation 
that the discrepancy can be observed giving rise to varied microeconomic and 
macroeconomic observations. 
For many communicable diseases in the developed and developing world the 
indirect costs of lost productivity will exceed the medical cost of a disease16, 17. 
Hence additional methods should be considered to capture the full benefi t 
of vaccination. Loss of productivity is quantifi ed using either the human 
capital or the friction cost method. The former assumes that the foregone 
output could be plausibly captured by the marginal product associated with a 
worker (summed over the period of illness, or the worker’s remaining time in 
the workforce). In practical terms, the loss in productivity cost for an illness 
calculated by the human capital method is the worker’s wage (the measure of 
his or her productivity) multiplied by the length of his or her absence from 
work18. The friction cost method estimates its cost by using the worker’s 
wage multiplied by the minimum length of absence and the average friction 
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period in the economy i.e the average duration of a vacancy until their labor 
has been replaced19. The underlying assumption is that the output lost is due 
to the friction in the labor market that restricts the ability of employers to 
fi nd a substitute for the sick worker, but in addition, the losses are limited 
to the time that is required for the worker to be replaced. Both the human 
capital and friction cost methods provide a monetary measurement either 
from the perspective of the individual or from the perspective of the fi rm, 
respectively20. The resulting monetary benefi t may be compared with the cost 
of vaccination in a cost-benefi t analysis which typically generates estimates 
of the Net Present Value or the Internal Rate of Return. 
Valuation of absenteeism requires evidence on the impact that a disease 
has on workdays lost, but a next stage of higher precision on productivity 
assessment is the quantifi cation of “presenteeism”. This is even more 
diffi  cult to assess correctly than absenteeism, since data on productivity of 
disease-impacted workers while at work is scarcely available and prospective 
data collection is needed. Nevertheless, survey methods, using metrics of 
productivity while at work have been developed21 and could be employed to 
quantify the productivity eff ect aside from the mere measurement of absence 
from work. Thus, some specifi c methods may be able to capture a fragment of 
signifi cant broader consequences. In addition, through econometric methods 
the broader consequences of educational attainment and school attendance 
may be integrated to assess the benefi ts of preventing a communicable disease 
on individuals’ lifetime earnings. 
Lastly, another method originating from the theory of microeconomics that 
evaluates the overall value of a new intervention within a broader context 
is the “contingent valuation method”. According to this survey method, 
respondents are asked to evaluate a question and place a value upon a 
hypothetical market product described22. The “contingent valuation method” 
collects preference information from the respondents by asking them how 
willing they would be to pay for the provision of a health care service or how 
willing they are to pay in order to avoid a disease. The results of this survey 
method are expressed in monetary terms and hence they can be used in a 
cost-benefi t analysis of a vaccination. Depending on the design of the survey, 
“contingent evaluation methods” may provide with estimates of the value 
that the society attributes to the reduction of risk of infection after taking 
into account an array of intangible benefi ts (e.g. ability to save money, food 
security, risk of catastrophic expenditure, fertility). The “contingent valuation 
method” reveals individuals’ preferences and valuation which, in turn, 
implicitly takes into account several evaluations that individuals consider 
prior to deciding on their economic and social behaviors. 
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The intangible broader benefi ts of health would be immediately recognizable 
to individuals because these attributes refl ect the way that people live. As such, 
contingent valuation may be able to quantify a range of broader consequences 
as attributes with corresponding monetary values assigned to these benefi ts. 
The comprehensive nature of the method suggests that individuals factor in a 
range of parameters likely to be relevant to macroeconomic analysis. Hence, 
contingent valuation estimates are greater than disease burden estimates due 
to the interpretation of these future benefi ts that would not be captured using 
microeconomic analysis alone. 
Macroeconomic analysis
Macroeconomic analytical methods typically apply retrospective cross-
country time series data to assess the impact of a disease on the Gross 
Domestic Product (GDP) per capita after controlling for confounding factors. 
They can follow an assessment across diff erent economic sectors including 
health care but at the country level. Such models have been used to assess 
the macroeconomic impact of malaria, tuberculosis and HIV to estimate 
the impact of disease on GDP23. Importantly they don’t always defi ne the 
precise mechanism by which a communicable disease infl uences economic 
growth. In addition, econometric analyses combine aggregate secondary 
macroeconomic and epidemiological data. Macroeconomic models may omit, 
due to the absence of detailed historical data, critical variables such as access 
to health care per country, health care infrastructure, or adoption of health 
technology per country. Moreover, the estimation and isolation of the benefi ts 
of vaccinations on the GDP require suffi  cient retrospective data from countries 
with vaccination programs. The collection of prospective macroeconomic 
and epidemiological data with the view of assessing the relationship between 
prevention of a communicable disease and the macro economy could be very 
time-consuming and resource intensive. Nevertheless, these methods may 
inform robust cross-country economic analyses of vaccination benefi ts. 
The availability of GDP estimates linked to health investment and health status 
changes and compared with microeconomic estimates might help to estimate 
economic multipliers. For instance, dramatically reducing malaria disease in 
a region may improve the economy overall of the region, as parents may better 
care for their children to give better education. It is conceivable that should 
these multipliers be identifi ed, they could be applied in microeconomic 
models as well to account for underestimates obtained. The identifi cation 
of multipliers is already established in fi scal policy recognizing that public 
investments can lead to greater returns than the actual fi scal investment. In 
this context one can envisage that multipliers could be applied to health to 
refl ect broader consequences of health gains in microeconomic analysis24. 
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The added value of macroeconomic assessment
The mechanism by which a disease infl uences the economy is multifactorial 
with large economic externalities likely associated with the prevention of highly 
burdensome diseases25, 26. A recent systematic review of studies evaluating the 
broader economic impact of vaccination in low and middle income countries 
identifi ed a diversifi ed set of categories27. They ranged from cost savings, 
increased productivity, to ecological externalities, infl uencing fertility rates, 
and longer-term economic sustainability. The use of broader economic benefi t 
variables for vaccines implies that there isn’t always a perfectly match between 
the results of micro- and macro- economic assessment. 
Undoubtedly the most dramatic consequence of infectious diseases is 
mortality. In addition to quantifying the cost of dying (e.g. terminal care, 
funeral costs), microeconomic methods have measured the mortality impact on 
foregone lifetime earnings. Meanwhile increased mortality may have broader 
consequences. The impact of vaccination on mortality may be regarded as 
a microeconomic benefi t fi rst which can be quantifi ed. It may subsequently 
have an impact on the change in fertility rates that infl uence the demographic 
composition and may be deemed as a broader consequence for which 
quantifi cation is more complex and may take considerable time (generations) 
to illustrate the impact28. Endemic malaria aff ects the demographic structure of 
a society, as the mortality burden falls mainly on infants and children under the 
age of fi ve. Young-age mortality as a result of malaria and/or HIV/AIDS infection 
reduces the macroeconomic prospects of aff ected countries17. There are similar 
scenarios as in the recent SARS outbreak causing a high mortality rate, but 
where the greatest impact was felt not in the health care sector but in tourism 
and travel sectors, which would aff ect the GDP directly29.
Moreover, the persistence and high prevalence of communicable diseases are 
likely to exacerbate the economic impact by altering the social and economic 
behavior of individuals. At the individual level, when a communicable 
disease is circulating in the community, the perception of infection’s risk will 
likely infl uence short- and long-term economic decision-making17. Hence, in 
countries where HIV/AIDS is highly prevalent, individuals may consume and 
invest less in order to protect themselves against the possibility of disease-
related catastrophic expenditure17. Altered consuming and investing decisions 
may negatively aff ect the sustainability of the economy as they reduce capital 
formation by discouraging individuals from saving. In addition, capital 
shortages and reduced consuming may discourage foreign investors. 
The fear of infection may also impact mobility which may have a cross-
sectorial impact that limits trade. Furthermore, the aff ected households 
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may divert productive resources to caring and high prevalence of endemic 
diseases divert public resources to health care and thus limit the funds for 
investment in other sectors. Furthermore, communicable diseases such as 
malaria may interfere with long-term cognitive development30. The long-
term neurological sequel of malaria, the presence of anemia, but also the 
uncomplicated malaria episodes are thought to impact school attendance, 
educational attainment, drop-out rates and overall cognitive development. 
These consequences are seldom quantifi ed in economic terms31. 
In human capital economics, the most explored causal relationship is between 
earnings and quantity and/or level of education attained32, 33, 34, 35. Reduced school 
performance has some immediate societal cost implications but more importantly, 
it may reduce lifetime opportunities because of education-linked wage eff ects 
that will persist over the course of life36, 37, 38. It translates to lower lifetime earnings 
that may result in less tax revenues and thus fewer resources available for public 
investments which could vitalize the economy38. In addition, reducing a country’s 
human capital accumulation may undermine an economy’s long-term prospects, 
its competitiveness, and its attractiveness to foreign investors. 
A prominent and well-studied economic parameter relates to labor 
productivity. A highly endemic communicable disease may result in sick-
days (absenteeism). Sick-days pose a burden to the individuals as they may 
represent a considerable proportion of an individual’s earnings. In addition, 
sick-days result in substantial loss for the fi rm which reduces its profi tability. 
Furthermore, reduced productivity while at work (presenteeism) may pose a 
substantial economic burden on fi rms due the productive output foregone. 
Although the friction cost method suggests the work can be made up or 
performed by colleagues the absolute output reduced can be extrapolated. 
Projecting productivity to a group of fi rms that operate within an aff ected 
area constitutes a perfect example of broader consequence which in the 
long run undermines macroeconomic growth through the reduction of total 
productivity and foreign investments. Projecting productivity to a group 
of fi rms that operate within an aff ected area constitutes a good example of 
broader consequence which may undermine macroeconomic growth through 
the reduction in total productivity and foreign investment. These elements 
are neglected in microeconomic analysis. 
Figure 1 illustrates the mechanisms with which a communicable disease may 
infl uence the broader economy. The multi-dimensional relationship between 
the economy and communicable diseases suggest that a preventative measure 
such as vaccination may benefi t the economy in multiple ways and benefi ts 
transcend the microeconomic value to individuals and households. An array 
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of broader benefi t appears to intermediately aff ect the economy and magnify 
the microeconomic economic consequences of a communicable disease 
and therefore the benefi t of prevention. The critical broader benefi t that 
originates from the prevention of highly burdensome communicable diseases 
may have large macroeconomic consequences which need to be considered 
quantitatively or qualitatively in the analysis and policy decision-making 
process. Quantifying the microeconomic benefi t appears to be relatively 
straightforward however; microeconomic consequences appear to be isolated 
to those that are immediately measurable, and a small fraction of the potential 
macroeconomic benefi t. In what follows, a short description of the current 
economic evaluation methods is presented and the extent to which they can 
integrate the quantifi cation of broader benefi t is discussed.
Figure 1 Communicable diseases and the economy 
3. Macroeconomic effect GDP
1 . Microeconomic effect
• Mortality, morbidity 
• Direct medical costs 
(pharmaceuticals; outpatient visits; 
hospitalizations)
• Out-of-pocket payments
• Travel costs; funeral costs
• (presenteeism & abseentism for 
firms and individuals)
• Care-giving needs  
• Resources allocated to children 
educations
• School a­endance/achievement 
• Cognitive development
• Lifetime wage prospects 
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• Mobility 
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Filling the micro-macro void 
Vaccinations off er far reaching economic benefi ts in both short and long term 
periods. Economic theory provides microeconomic and macroeconomic 
methods for evaluating the benefi ts of vaccinations. They are often fi rst 
projected using microeconomic methods that demonstrate how vaccines 
can generate productivity gains through reduced morbidity and mortality. 
Establishing the causality between vaccines at the macroeconomic level is 
more diffi  cult to obtain due to the societal transformations that vaccines 
can provide. Vaccines may result in a cluster of transitional or broader 
consequences which may have a considerable impact on the macro-economy. 
They not only save lives but they change behavior and investment choices 
domestically and internationally. For example, investigations have noted 
diff erences in GDP per capita between countries based on the presence or 
absence of malaria23. However, causality at the macro level requires knowledge 
about the far-reaching aspects of societal change that will occur in order to 
make macro level predictions. In addition, a population-based vaccination 
may improve the quality and patterns of care provided within a country by 
preventing a substantial number of cases in need of secondary or tertiary 
care. Thus, although vaccination may increase the quality, effi  ciency and 
the productivity of a health care system, the benefi t of a population-based 
vaccination may take several years to materialize and prospective studies are 
needed to generate the corresponding evidence. 
Microeconomic and macroeconomic analyses off er useful policy-making 
tools. Microeconomic analyses may inform budget-effi  cient decisions and 
inform scarce resource allocation decisions within the health care system. 
Absenteeism quantifi cation methods quantify the value of productivity 
loss which represents the most considerable cost component in developing 
countries. Contingent valuation methods are well established theoretically and 
may be valuable for countries with high out of pocket payments. The results of 
macroeconomic analyses are presented in terms of GDP thus; they allow the 
comparison of vaccinations with other interventions across diff erent sectors 
(e.g. transportation, environment, education). Macroeconomic analyses may 
off er a tool for cross-sectorial or general government (or foreign aid) effi  cient 
budget allocation of resources. Macroeconomic analyses may be used to 
benchmark countries and identify best practices and thus, inform future 
policy that could be internationally implemented. Although of limited value 
to health care budget holders macroeconomic analyses may be particularly 
relevant for international organizations and general governments. 
The broader consequences of vaccinations may resemble what Schumpeter 
described as “meso-economic” which constitutes “a structure component of 
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a ‘deep’ invisible macro structure”39. The concept of the meso-economy is a 
debatable construct of which a thorough analysis is beyond the scope of this 
paper. What this paper advocates is that this domain could also be thought of 
as a gateway by which the micro and macro economy of health are joined (see 
Figure 1). Currently available economic evaluation methods typically omit 
these consequences however; they may be adjusted to integrate some of the 
“meso-economic” consequences. 
The observed gap between micro and macro estimates in health presents 
challenges to our understanding of health-related economic benefi ts and how 
one might address the gap methodologically. Foremost the micro-macro gap 
suggests that microeconomic methods applied in health do not adequately 
refl ect the broader economic benefi ts that can be achieved through health-
status gains. The underestimates provided by current microeconomic 
methods would likely vary as the broader consequences would vary for 
diff erent health care investments. For example, the broader consequences 
associated with paediatric immunization programs; prostate cancer screening 
and cancer interventions would all be diff erent, therefore infl uencing the 
micro-macro gap diff erently.
In the previous section we proposed the concept of multipliers that could 
be derived to better understand the relationship between micro and macro 
health models. Because the externalities attributed to health vary at diff erent 
stages of life and nature of illness, this would suggest that multipliers 
applied to health investments would also vary depending on the nature 
of the condition and age of the individual. In this sense one can imagine 
potential weights for diff erent medical conditions that could be applied to 
microeconomic estimates to understand the macroeconomic consequences 
of specifi c interventions.
Another promising way to assess the link between micro- and macro-economic 
levels related to health investment is the use of model-based analytic methods 
that have been recently developed to assess the impact of vaccination against 
communicable diseases, the computable general equilibrium models (CGE)8. 
CGE models usually depend on Social Accounting Matrices (SAM) for national 
income and input-output data. The underlying assumptions of CGE models 
are that evidence regarding a cluster of broader consequences as described 
in Figure 1 can be modelled to simulate the impact of a disease on the macro-
economy. CGE models factor in institutional sectors of the economy including 
government, households, the main economic sectors (e.g. manufacturing, 
agriculture, banking, tourism and transport etc.), capital, and labor as well as 
foreign trade. CGE methods have been used to assess the impact of pandemic 
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infl uenza on the UK economy8. It was modelled in terms of reducing the 
quantity and quality of labor supply. They are the instruments that assess the 
details at micro level, but evaluate the overall benefi t and cost at macro level. 
Those models assumed that labor supply would be aff ected either through 
high mortality or through absenteeism and reduced productivity at work 
(presenteeism). 
CGE models have been extensively used for years to inform development 
policies across several countries40. A recent study assessed, using a 
dynamic CGE model, the impact of malaria on the economy of Ghana41. 
The study assessed the impact on the GDP per capita as well as the income-
distributional eff ect of malaria-preventing strategies by taking into account 
labor size and productivity (presenteeism and absenteeism). Current, CGE 
models are heavily relied on assumptions regarding the consequence of a 
communicable disease on economic behaviors. For CGE models to generate 
pragmatic estimates of the macroeconomic impact, collecting and collating 
survey evidences, shedding light to the impact of communicable diseases on 
a variety of economic behaviors, are needed by constructing a valid analytical 
framework for the overall economy. Nevertheless, they can provide with a 
comprehensive quantifi cation of the overall economic impact of a vaccination 
by modelling a variety of broader consequences that can help to fi ll the micro-
macro gap. 
Conclusion
There are reasons to believe that for high burden communicable diseases 
able to spread across an entire community that a full economic package 
encompassing microeconomic and macroeconomic analyses about new 
interventions such as vaccines is warranted to inform resource allocation 
decisions. Each type of analysis may not come to precisely the same end-
result about cost-eff ectiveness evaluation when done separately (See Table 1). 
Meanwhile there are methods/techniques now available that could facilitate 
to build up a more direct link between the two levels of assessments such as 
CGE. It should also be further explored if meso-economics as a new domain 
of existing in economics could help explaining the discrepancies observed in 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Novel Economic Perspectives on Prevention and Treatment
126
References
1. Alleyne, GAO, Cohen D. Health, economic growth and poverty reduction: 
the report of Working Group I of the Commission on Macroeconomics 
and Health. World Health Organization, Geneva; 2002.
2. Suhrcke M, McKee M, Arce, RS, Tsolova S, Mortensen J. The contribution 
of health to the economy in the European Union. Public Health 
2006;120:994-1001. 
3. Jack W, Lewis M. Health investments and economic growth: 
Macroeconomic evidence and microeconomic foundations. World Bank, 
Washington DC; 2009. 
4. Schultz, TP. Assessing the productive benefi ts of nutrition and health: 
An integrated human capital approach. J Econom 1997;77:141–58.
5. Preston SH. The changing relation between mortality and level of 
economic development. Popul Stud 1975;2:231-48. 
6. Pritchett L, Summers L. Wealthier is healthier. J Hum Resour 1996;31:841-68.
7. Ehreth J. The global value of vaccination. Vaccine 2003;21:596–600. 
8. Smith DR, Keogh-Brown MR, Barnett T, Tait J. The economy-wide impact 
of pandemic infl uenza on the UK: a computable general equilibrium 
modelling experiment. BMJ 2009;339:b4571 doi:10.1136/bmj. B4571.
9. Almond D. Is the 1918 infl uenza pandemic over? Long-term eff ects of in 
utero infl uenza exposure in the post 1940 U. S. population. J Polit Econ 
2006;114: 672-712.
10. Brainerd E, Siegler MV. The economic eff ects of the 1918 infl uenza 
epidemic. Discussion paper 3791. Center for Economic Policy Research 
(CEPR); 2003.
11. Rees N, Chai J, Anthony D. Right in principle and in practice: A review of 
the social and economic returns to investing in children. United Nations 
Children’s Fund (UNICEF) Division of Policy and Strategy, New York; 2012.
12. Malaney P, Spielman A, Sachs J. The malaria gap. Am J Trop Med Hyg 
2004;71:(2S)141–6.
13. Connolly MP, Topachevskyi O, Standaert B, Ortega O, Postma MJ. The 
impact of rotavirus vaccination on discounted net tax revenue in Egypt. 
PharmacoEconomics 2012;30:681-895.
14. Postma MJ, Standaert BA. Economics of vaccines revisited. Human 
Vaccines &Immunotherapeutics 2013;9:1–3.
15. Drummond MF, ‘O’Brien B, Stoddart GL, Torrance GW. Methods for the 
economic evaluation of health care programmes. 2nd ed. Oxford: Oxford 
University Press; 1997.
16. Standaert B, Harlin O, Desselberger U. The fi nancial burden of rotavirus 




17. Russell S. The economic burden of illness for households in developing 
countries: A review of studies focusing on malaria, tuberculosis and 
human immunodefi ciency virus/acquired immunodefi ciency syndrome. 
Am J Trop Med Hyg 2004;71:(2S)147-55.
18. Mushkin SJ, Smelker M, Wyss D, Vehorn CL, et al. Cost of disease and 
illness in the United States in the year 2000. Public Health Rep 1978; 
93:493–588. 
19. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost 
method for measuring indirect costs of disease. J Health Econ 1995; 14:171-89. 
20. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss 
due to poor health: A critical review. Soc Sci Med 2011;72:185-92. 
21. Reilly MC, Zbrozek AS, Dukes EM. The validity and 
reproducibility of a work productivity and activity impairment 
instrument. Pharmacoeconomics 1993;4:353–365.
22. Johansson PO. Evaluating health risks: an economic approach. 
Cambridge: Cambridge University Press; 2005. 
23. Gallup JL, Sachs JD. The economic burden of malaria. Am J Trop Med Hyg 
2001;64:(1-2S)85-96.
24. Congressional Budget Offi  ce (CBO). Estimated Impact of the American 
Recovery and Reinvestment Act on employment and economic output 
from January 2012 through March 2012. Available from: http://www. 
Cbo. Gov/sites/default/fi les/cbofi les/attachments/ARRA_One-Col. Pdf
Accessed May 2013. 
25. European Commission. Investing in health – Commission staff  working 
document. Available from: http://ec. Europa. Eu/health/strategy/docs/
swd_investing_in_health. Pdf Accessed November 2013.
26. World Health Organization. WHO guide to identifying the economic 
consequences of disease and injury; 2009. Available at: http://www. Who. 
Int/choice/publications/d_economic_impact_guide. Pdf Accessed May 2013.
27. Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M. Systematic 
review of studies evaluating the broader economic impact of vaccination 
in low and middle income countries. BMC Public Health. 2012; 16; 12:878
28. Zhang J, Zhang Ji, Lee,R. Mortality decline and long-run economic 
growth Journal of Public Economics. 2001;80: 485-507
29. Keogh-Brown MR, Smith RD. The economic impact of SARS: how does 
the reality match the predictions? Health Policy 2008;88:110-20.
30. Holding PA, Snow RW. Impact of  Plasmodium falciparum  malaria on 
performance and learning: review of the evidence. Am J Trop Med Hyg 
2001;64:(1-2S)68–75.
31. Bleakley, Hoyt. 2010. “Malaria Eradication in the Americas: A 
Retrospective Analysis of Childhood Exposure. American Economic 
Journal: Applied Economics; 2(2): 1-45.
Novel Economic Perspectives on Prevention and Treatment
128
32. Mincer J. Schooling, experience and earnings. New York: Columbia 
University Press; 1974.
33. Grossman M. 1975. The correlation between health and schooling: 
household production and consumption. In: Terleckyj NE, editor. 
Studies in income and wealth, vol. 40. New York: Columbia University 
Press; 1975.
34. Psacharopoulos G, Layard R. Human capital and earnings: British evidence 
and critique. The Review of Economic Studies 1979;46: 485-503.
35. Psacharopoulos G. Returns to education: an updated international 
comparison. Comparative Education 1981;17: 321-41.
36. Becker GS. Human Capital: A theoretical and empirical analysis, with 
special referenceto education. Chicago: University of Chicago Press; 1964.
37. Organisation for Economic Co-operation and Development (OECD). 
Lifelong learnings and human capital; 2007. Available from http://
wwwoecd org/dataoecd/43/50/38982210pdf Accessed October 2011.
38. Kotsopoulos N, Connolly MP, Sobanski E, Postma MJ. The fi scal 
consequences of ADHD in Germany: A quantitative analysis based on 
diff erences in educational attainment and lifetime earnings. J Ment 
Health Policy Econ 2013;16: 27-33.  
39. Dopfer K. The origins of meso economics Schumpeter’s legacy; 
2006. Available from: http://www. Econstor. Eu/dspace/
bitstream/10419/31822/1/518423085. Pdf Accessed May 2013. 
40. Bandara JS. Computable general equilibrium models for development 
policy analysis in LDCs. J Econ Surv 1991;5:3–69.
41. Yerushalmi E, Hunt PE, Hoorens S, Sauboin C, Smith RD. The macro-
economic impact of reducing malaria: An application of a dynamic 
general equilibrium modeling to Ghana. Value Health 2012;15:A400.
